Expertise in
1
conditions

Dr. Wendy R. Bond

Neurology
Alzheimers Diagnostic Centers
3033 Winkler Ave Unit 200, 
Fort Myers, FL 
Expertise in
1
conditions
Alzheimers Diagnostic Centers
3033 Winkler Ave Unit 200, 
Fort Myers, FL 

Overview

Wendy Bond is a Neurologist practicing medicine in Fort Myers, Florida.

Dr. Bond is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Dementia, and Spinal Muscular Atrophy (SMA).

She is actively involved in clinical research, participating in 14 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Alzheimers Diagnostic Centers
3033 Winkler Ave Unit 200, Fort Myers, FL 33916

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
Enrollment Status: Completed
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drug: Pepinemab
Study Phase: Phase 1/Phase 2
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
7
conditions
Expertise in
7
conditions
Referral may be required

Office

11215 Metro Pkwy Bldg 3, 
Fort Myers, FL 
 (3.2 miles away)
239-208-2212
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sara Hocker is a Neurologist practicing medicine in Fort Myers, Florida. Dr. Hocker is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Status Epilepticus, Seizures, Encephalitis, Epilepsy, and Embolectomy. Dr. Hocker is currently accepting new patients.

Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Neuroscience & Spine Associates

1660 Medical Blvd Ste 200, 
Naples, FL 
 (23.5 miles away)
239-566-3434
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Novak is a Neurologist practicing medicine in Naples, Florida. Dr. Novak is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Migraine, Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, Familial Paroxysmal Nonkinesigenic Dyskinesia, and Dopa-Responsive Dystonia. Dr. Novak is currently accepting new patients.

Expertise in
62
conditions
Expertise in
62
conditions
Referral may be required

Physicians Regional-Pine Ridge

6101 Pine Ridge Rd, 
Naples, FL 
 (30.0 miles away)
239-649-1662
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Wey Ii is a Neurologist practicing medicine in Naples, Florida. Dr. Wey Ii is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Congenital Insensitivity to Pain with Anhidrosis, Infantile Axonal Neuropathy, Hereditary Sensory and Autonomic Neuropathy Type 2, and Fractured Spine. Dr. Wey Ii is currently accepting new patients.

Frequently Asked Questions about Dr. Wendy R. Bond

How do I make an appointment with Dr. Wendy R. Bond?

You can book an appointment with Dr. Wendy R. Bond by calling their office at 239-277-0200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Wendy R. Bond a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Wendy R. Bond is classified as an Advanced expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Wendy R. Bond specialize in?

While Dr. Wendy R. Bond is a Neurology, they have specific expertise in Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Dementia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Wendy R. Bond accept my insurance?

Dr. Wendy R. Bond accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 239-277-0200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bond's expertise for a condition
ConditionClose
      View All 24 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile